When a biotech darling gets FDA-snubbed, investors feel the burn. In this episode of Sue Wall Street, we dig into the class action lawsuit against $REPL Replimune after its cancer trial bombed and the FDA called it “not adequate or well-controlled.” If you're a biotech investor, trader, or market skeptic, this one’s for you. Expect sharp commentary, legal breakdowns, and eye-popping stock drops as we unpack what went wrong — and what comes next.

Visit ZLK.com for more info.